EIGHTH GADDUM MEMORIAL LECTURE UNIVERSITY OF LONDON INSTITUTE OF EDUCATION DECEMBER 1980: BIOLOGICAL IMPORTANCE OF PROSTACYCLIN
1982; Wiley; Volume: 76; Issue: 1 Linguagem: Inglês
10.1111/j.1476-5381.1982.tb09186.x
ISSN1476-5381
Autores Tópico(s)Phytochemistry and Bioactive Compounds
ResumoBritish Journal of PharmacologyVolume 76, Issue 1 p. 3-31 Free Access EIGHTH GADDUM MEMORIAL LECTURE UNIVERSITY OF LONDON INSTITUTE OF EDUCATION DECEMBER 1980: BIOLOGICAL IMPORTANCE OF PROSTACYCLIN SALVADOR MONCADA, SALVADOR MONCADA Department of Prostaglandin Research, Langley Court, Beckenham, Kent BR3 3BSSearch for more papers by this author SALVADOR MONCADA, SALVADOR MONCADA Department of Prostaglandin Research, Langley Court, Beckenham, Kent BR3 3BSSearch for more papers by this author First published: May 1982 https://doi.org/10.1111/j.1476-5381.1982.tb09186.xCitations: 252AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References ADELMAN, B., STEMERMAN, M.B., MENDELL, D. & HANDIN, R.I. (1981). The interaction of platelets with aortic subendothelium: inhibition of adhesion and secretion by prostaglandin I2. Blood, 58, 198–205. CASPubMedWeb of Science®Google Scholar AGER, A., GORDON, J.L., MONCADA, S., PEARSON, J.D., SALMON, J.A. & TREVETHICK, M.A. (1982). Effects of isolation and culture on prostaglandin synthesis by porcine aortic endothelial and smooth muscle cells. J. cell. Physiol., (in press). 10.1002/jcp.1041100103 PubMedWeb of Science®Google Scholar AIKEN, J.W. (1979). Discussion of chapter by R.J. Gryglewski: Is the lung an endocrine organ that secretes prostacyclin? In Prostacyclin ed. J.R. Vane & S. Bergström p. 287. New York: Raven Press. Google Scholar AIKEN, J.W., GORMAN, R.R. & SHEBUSKI, R.J. (1979). Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins, 17, 483–494. 10.1016/0090-6980(79)90001-7 CASPubMedWeb of Science®Google Scholar ALI, A.E., BARRETT, J.C. & ELING, T.E. (1980). Prostaglandin and thromboxane production by fibroblasts and vascular endothelial cells. Prostaglandins, 20, 667–668. 10.1016/0090-6980(80)90107-0 CASPubMedWeb of Science®Google Scholar AMEZCUA, J-L., O'GRADY, J., SALMON, J.A. & MONCADA, S. (1979). Prolonged paradoxical effect of aspirin on behaviour and bleeding time in man. Thromb. Res., 16, 69–79. 10.1016/0049-3848(79)90270-6 CASPubMedWeb of Science®Google Scholar AMEZCUA, J-L., PARSONS, M. & MONCADA, S. (1978). Unstable metabolites of arachidonic acid, aspirin and the formation of the haemostatic plug. Thromb. Res., 13, 477–488. 10.1016/0049-3848(78)90133-0 CASPubMedWeb of Science®Google Scholar ARFORS, K-E., BERGQVIST, D. & TANGEN, O. (1975). The effect of platelet function inhibitors on experimental venous thrombosis formation in rabbits. Acta. chir. scand., 141, 40–42. CASPubMedWeb of Science®Google Scholar AUSTEN, K.F. (1978). Homeostasis of effector systems which can also be recruited for immunologic reactions. J. Immunol., 121, 793–805. CASPubMedGoogle Scholar BANG, H.O. & DYERBERG, J. (1972). Plasma lipids and lipoproteins in Greenland West Coast Eskimos. Acta. med. scand., 192, 85–94. 10.1111/j.0954-6820.1972.tb04782.x PubMedWeb of Science®Google Scholar BAUMGARTNER, H.R. & MUGGLI, R. (1974). Effect of acetylsalicylic acid on platelet adhesion to subendothelium and on the formation of mural platelet thrombi in vivo. Thromb. Diath. Haemorrh. Suppl., 60, 345–354. CASGoogle Scholar BAYER, B-L., BLASS, K-E. & FÖRSTER, W. (1979). Antiaggregatory effect of prostacyclin (PGI2) in vivo. Br. J. Pharmac., 66, 10–12. 10.1111/j.1476-5381.1979.tb16090.x CASPubMedWeb of Science®Google Scholar BEITZ, J. & FÖRSTER, W. (1980). Influence of human low density and high density lipoprotein cholesterol on the in vitro prostaglandin I2 synthetase activity. Biochim. biophys. Acta., 620, 352–355. 10.1016/0005-2760(80)90126-5 CASPubMedWeb of Science®Google Scholar BENDIT, E.P. (1977). The origin of atherosclerosis. Sci. Am., 236, 74–85. 10.1038/scientificamerican0277-74 PubMedWeb of Science®Google Scholar BERGMAN, G., DALY, R., ATKINSON, L., ROTHMAN, M., RICHARDSON, P.J., JACKSON, G. & JEWITT, D.E. (1981). Prostacyclin: haemodynamic and metabolic effects in patients with coronary artery disease. Lancet, i, 569–572. 10.1016/S0140-6736(81)92028-6 CASGoogle Scholar BEST, L.C., MARTIN, T.J., RUSSELL, R.G.G. & PRESTON, F.E. (1977). Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. Nature, Lond., 267, 850–851. 10.1038/267850a0 CASPubMedWeb of Science®Google Scholar BHATTACHERJEE, P., KULKARNI, P.S. & EAKINS, K.E. (1979). The metabolism of arachidonic acid in rabbit ocular tissue. Invest. Ophthalmol., 18, 172–178. CASPubMedWeb of Science®Google Scholar BLACK, R.L., CULP, B., MADISON, D., RANDALL, O.S. & LANDS, W.E.M. (1979). The protective effects of dietary fish oil on focal cerebral infarction. Prostaglandins Med., 3, 257–268. 10.1016/0161-4630(79)90067-3 CASPubMedWeb of Science®Google Scholar BLACKWELL, G.J., FLOWER, R.J., RUSSELL-SMITH, N., SALMON, J.A., THOROGOOD, P.B. & VANE, J.R. (1978). l-n-Butylimidazole: a potent and selective inhibitor of 'Thromboxane Synthetase. Br. J. Pharmac., 64, 436P. CASPubMedWeb of Science®Google Scholar BLAIR, I.A., BARROW, S.E., WADDELL, K.A., LEWIS, P.J. & DOLLERY, C.T. (1982). Analysis of 6-oxo-prostaglandin Flα in human plasma by gas chromatography negative chemical ionisation mass spectrometry. Prostaglandins., (in press). Google Scholar BLASKO, G., NEMESANSZKY, E., SZABO, G., STADLER, I. & PALOS, L.A. (1980). The effect of PGI2 and PGI2 analogues with increased stability on platelet cAMP content and aggregation. Thromb. Res., 17, 673–681. 10.1016/0049-3848(80)90370-9 CASPubMedWeb of Science®Google Scholar BORGEAT, P., HAMBERG, M. & SAMUELSSON, B. (1976). Transformation of arachidonic acid and dihomo-γ-linolenic acid by polymorphonuclear leukocytes. J. biol. Chem., 251, 7816–7820. CASPubMedWeb of Science®Google Scholar BORN, G.V.R. (1962). Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, Lond., 194, 927–929. 10.1038/194927b0 CASPubMedWeb of Science®Google Scholar BOURGAIN, R.H. (1978). Inhibition of PGI2 (prostacyclin) synthesis in the arterial wall enhances the formation of white platelet thrombi in vivo. Haemostasis, 7, 252–255. CASPubMedWeb of Science®Google Scholar BOURGAIN, R.H., SIX, F. & ANDRIES, R. (1980). The action of cyclo-oxygenase and prostacyclin-synthetase inhibitors on platelet-vessel wall interaction. Artery, 8, 96–100. CASPubMedWeb of Science®Google Scholar BOXER, L.A., ALLEN, J.M., SCHMIDT, M., YODER, M. & BAEHNER, R.L. (1980). Inhibition of polymorphonuclear adherence by prostacyclin. J. lab. Clin. Med., 95, 672–678. CASPubMedWeb of Science®Google Scholar BOYD, A.M. & MARKS, J. (1963). Treatment of intermittent claudication. A reappraisal of the value of α-tocopherol. Angiology, 14, 198–208. 10.1177/000331976301400409 CASPubMedWeb of Science®Google Scholar BROX, J.H., KILLE, J-E., GUNNES, S. & NORDOY, A. (1981). The effect of cod liver oil and corn oil on platelets and vessel wall in man. Thromb. Haem., 46, 604–611. CASPubMedWeb of Science®Google Scholar BRUNE, K., GLATT, M., KALIN, H. & PESKAR, B.A. (1978). Pharmacological control of prostaglandin and thromboxane release from macrophages. Nature, Lond., 274, 261–263. 10.1038/274261a0 CASPubMedWeb of Science®Google Scholar BUCHANAN, M.R., DEJANA, E., CAZENAVE, J.P., MUSTARD, J.F. & HIRSH, J. (1979). Uncontrolled PGI2 production by whole vessel wall segments due to thrombin generation in vivo and its prevention by heparin. Thromb. Res., 16, 551–555. 10.1016/0049-3848(79)90102-6 CASPubMedWeb of Science®Google Scholar BUDD, G.T., BUKOWSKI, R.M., LUCAS, F.V., CATO, A.E. & COCCHETTO, D.M. (1980). Prostacyclin therapy of thrombotic thrombocytopenic purpura. Lancet, ii, 915. 10.1016/S0140-6736(80)92071-1 Google Scholar BUNTING, S., GRYGLEWSKI, R., MONCADA, S. & VANE, J.R. (1976b). Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins, 12, 897–913. 10.1016/0090-6980(76)90125-8 CASPubMedWeb of Science®Google Scholar BUNTING, S. & MONCADA, S. (1980). Prostacyclin, by preventing platelet activation, prolongs activated clotting time in blood and platelet rich plasma and potentiates the anti-coagulant effect of heparin. Br. J. Pharmac., 69, 268–269P. Google Scholar BUNTING, S., MONCADA, S., REED, P., SALMON, J.A. & VANE, J.R. (1978). An antiserum to 5,6-dihydro prostacyclin (PGI1) which also binds prostacyclin. Prostaglandins, 15, 565–574. 10.1016/0090-6980(78)90053-9 CASPubMedWeb of Science®Google Scholar BUNTING, S., MONCADA, S. & VANE, J.R. (1976a). The effects of prostaglandin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and other smooth muscle preparations. Br. J. Pharmac., 57, 462–463P. CASPubMedWeb of Science®Google Scholar BUNTING, S., MONCADA, S. & VANE, J.R. (1977). Antithrombotic properties of vascular endothelium. Lancet, ii, 1075–1076. 10.1016/S0140-6736(77)91906-7 Google Scholar BUNTING, S., MONCADA, S., VANE, J.R., WOODS, H.F. & WESTON, M.J. (1979). Prostacyclin improves hemocompatibility during charcoal hemoperfusion. In Prostacyclin. ed. J.R. Vane & S. Bergström pp. 361–369. New York: Raven Press. Google Scholar BUNTING, S., SIMMONS, P.M. & MONCADA, S. (1981). Inhibition of platelet activation by prostacyclin: possible consequences in coagulation and anti-coagulation. Thromb. Res., 21, 89–102. 10.1016/0049-3848(84)90036-7 CASPubMedWeb of Science®Google Scholar BURCH, J.W., BAENZIGER, N.L., STANFORD, N. & MAJERUS, P.W. (1978). Sensitivity of fatty acid cyclo-oxygenase from human aorta to acetylation by aspirin. Proc. natn. Acad. Sci. U.S.A., 75, 5181–5184. 10.1073/pnas.75.10.5181 CASPubMedWeb of Science®Google Scholar CARRERAS, L.O., CHAMONE, D.A.F., KERCKX, P. & VERMYLEN, J. (1980). Decreased vascular prostacyclin (PGI2) in diabetic rats. Stimulation of PGI2 release in normal and diabetic rats by the antithrombotic compound Bayg6575. Thromb. Res., 19, 663–670. 10.1016/0049-3848(80)90038-9 CASPubMedWeb of Science®Google Scholar CHANG, H.C. & GADDUM, J.H. (1933). Choline esters in tissue extracts. J. Physiol. 79, 255–285. 10.1113/jphysiol.1933.sp003049 CASPubMedWeb of Science®Google Scholar CHANG, W-C., MUROTA, S-I., NAKAO, J. & ORIMO, H. (1980). Age-related decrease in prostacyclin biosynthetic activity in rat aortic smooth muscle cells. Biochim. biophys. Acta., 620, 159–166. 10.1016/0005-2760(80)90195-2 CASPubMedWeb of Science®Google Scholar CHIERCHIA, S., CIABATTONI, G., CINOTTI, G., MASERI, A., PATRONO, C., PUGLIESE, F., DISTANTE, A., SIMONETTI, I. & BERNINI, W. (1979). Hemodynamic and anti-aggregatory effects of prostacyclin (PGI2) in healthy man. Circulation, 60, part II, Abs. 318. Web of Science®Google Scholar CHO, M.J. & ALLEN, M.A. (1978). Chemical stability of prostacyclin (PGI2) in aqueous solutions. Prostaglandins, 15, 943–954. 10.1016/0090-6980(78)90037-0 CASPubMedWeb of Science®Google Scholar CHRIST, E.J. & VAN DORP, D.A. (1972). Comparative aspects of prostaglandins. Adv. Biosc., 9, 35–38. CASGoogle Scholar CHRISTOFINIS, G.J., MONCADA, S., BUNTING, S. & VANE, J.R. (1979). Prostacyclin (PGI2) release by rabbit aorta and human umbilical vein endothelial cells after prolonged subculture. In Prostacyclin. ed. J.R. Vane & S. Bergström pp. 77–84. New York: Raven Press. Google Scholar CIMO, P.L., MOAKE, J.L., WEINGER, R.S., BENMENACHEM, Y. & KHALIL, K.G. (1979). Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses. Am. J. Haematol., 6, 125–133. 10.1002/ajh.2830060204 CASPubMedWeb of Science®Google Scholar COCCHETTO, D.M., COOK, L., CATO, A.E. & NIEDEL, E. (1981). Rationale and proposal for use of prostacyclin in thrombotic thrombocytopenic purpura therapy. Seminars in Thrombosis and Haemostasis, 7, 43–51. 10.1055/s-2007-1005069 CASPubMedWeb of Science®Google Scholar COKER, S.J., PARRATT, J.R., LEDINGHAM, I. McA. & ZEITLIN, I.J. (1981). Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature, 291, 323–324. 10.1038/291323a0 CASPubMedWeb of Science®Google Scholar COUGHLIN, S.R., MOSKOWITZ, M.A., ZEITER, B.R., ANTONIADES, H.N. & LEVINE, L. (1980). Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor. Nature, 288, 600–602. 10.1038/288600a0 CASPubMedWeb of Science®Google Scholar CULP, B.R., LANDS, W.E.M., LUCCESI, B.R., PITT, B. & ROMSON, J. (1980). The effect of dietary supplementation of fish oil on experimental myocardial infarction. Prostaglandins, 20, 1021–1031. 10.1016/0090-6980(80)90056-8 CASPubMedWeb of Science®Google Scholar CULP, B.R., TITUS, B.G. & LANDS, W.E.M. (1979). Inhibition of prostaglandin biosynthesis by eicosapentaenoic acid. Prostaglandins Med., 3, 269–278. 10.1016/0161-4630(79)90068-5 CASPubMedWeb of Science®Google Scholar CURWEN, K.D., GIMBRONE, M.A. JR. & HANDIN, R.I. (1980). In vitro studies of thromboresistance. The role of prostacyclin (PGI2) in platelet adhesion to cultured normal and virally transformed human vascular endothelial cells. Lab. Invest., 42, 366–374. CASPubMedWeb of Science®Google Scholar CZERVIONKE, R.L., SMITH, J.B., FRY, G.L. & HOAK, J.C. (1979). Inhibition of prostacyclin by treatment of endothelium with aspirin. J. clin. Invest., 63, 1089–1092. 10.1172/JCI109379 CASPubMedWeb of Science®Google Scholar D'ANGELO, V., VILLA, S., MYSLIWIEC, M., DONATI, M.B. & DE GAETANO, G. (1978). Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb. Diath. Haemorrh., 39, 535–536. CASPubMedWeb of Science®Google Scholar DAVIDSON, E.M., FORD-HUTCHINSON, A.W., SMITH, M.J.H. & WALKER, J.R. (1978). The release of thromboxane B2 by rabbit peritoneal polymorphonuclear leukocytes. Br. J. Pharmac., 63, 407P. CASPubMedWeb of Science®Google Scholar DAVIS, T.M.E., BROWN, E., FINCH, D.R., MITCHELL, M.D. & TURNER, R.C. (1981). In vitro venous prostacyclin production, plasma 6-keto prostaglandin F1α concentrations, and diabetic retinopathy. Brit. med. J., 282, 1259–1262. 10.1136/bmj.282.6272.1259 CASPubMedWeb of Science®Google Scholar DEFREYN, G., DAYDEN, VERGARA M., MACHIN, S.J. & VERMYLEN, J. (1980). A plasma factor in uraemia which stimulates prostacyclin release from cultured endothelial cells. Thrombosis Res., 19, 695–699. 10.1016/0049-3848(80)90041-9 CASPubMedWeb of Science®Google Scholar DEJANA, E., CAZENAVE, J.-P., GROVES, H.M., KINLOUGH-RATHBONE, R.L., RICHARDSON, M., PACKHAM, M.A. & MUSTARD, J.F. (1980). The effect of aspirin inhibition of PGI2 production on platelet adherence to normal and damaged rabbit aortae. Thrombosis Res., 17, 453. 10.1016/0049-3848(80)90080-8 CASPubMedWeb of Science®Google Scholar DEMLING, R.H., SMITH, M., GUNTHER, R., GEE, M. & FLYNN, J. (1981). The effect of prostacyclin infusion on endotoxin-induced lung injury. Surgery, 89, 257–263. CASPubMedWeb of Science®Google Scholar DICZFALUSY, U., FALARDEAU, P. & HAMMARSTRÖM, S. (1977). Conversion of prostaglandin endoperoxides to C17-hydroxy acids catalyzed by human platelet thromboxane synthetase. Fed. Eur. Biochem. Soc. Lett., 84, 271–274. 10.1016/0014-5793(77)80704-7 CASPubMedWeb of Science®Google Scholar DOLLERY, C.T., FRIEDMAN, L.A., HENSBY, C.N., KOHNER, E., LEWIS, P.J., PORTA, M. & WEBSTER, J. (1979). Circulating prostacyclin may be reduced in diabetes. Lancet, ii, 1365. 10.1016/S0140-6736(79)92844-7 CASGoogle Scholar DUSTING, G.J., MONCADA, S. & VANE, J.R. (1977). Disappearance of prostacyclin in the circulation of the dog. Br. J. Pharmac., 62, 414–415P. Google Scholar DUSTING, G.J., MONCADA, S. & VANE, J.R. (1978a). Recirculation of prostacyclin (PGI2) in the dog. Br. J. Pharmac., 64, 315–320. 10.1111/j.1476-5381.1978.tb17307.x CASPubMedWeb of Science®Google Scholar DUSTING, G.J., MONCADA, S. & VANE, J.R. (1978b). Vascular actions of arachidonic acid and its metabolites in perfused mesenteric and femoral beds of the dog. Eur. J. Pharmac., 49, 65–72. 10.1016/0014-2999(78)90222-4 CASPubMedWeb of Science®Google Scholar DUSTING, G.J. & MULLINS, E.M. (1980). Stimulation by angiotensin of prostacyclin biosynthesis in rats and dogs. Clin. exp. Pharmac. Physiol., 7, 545–550. 10.1111/j.1440-1681.1980.tb00108.x CASPubMedWeb of Science®Google Scholar DYERBERG, J. & BANG, H.O. (1979). Haemostatic function and platelet polyunsaturated fatty acids in eskimos. Lancet, ii, 433–435. 10.1016/S0140-6736(79)91490-9 CASWeb of Science®Google Scholar DYERBERG, J. & JORGENSEN, K.A. (1980). The effect of arachidonic- and eicosapentaenoic acid on the synthesis of prostacyclin-like material in human umbilical vasculature. Artery, 8, 12–17. CASPubMedWeb of Science®Google Scholar DYERBERG, J., BANG, H.O., STOFFERSEN, E., MONCADA, S. & VANE, J.R. (1978). Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis Lancet, ii, 117–119. 10.1016/S0140-6736(78)91505-2 CASGoogle Scholar ELDOR, A., FALCONE, D.J., HAJJAR, D.P., MINICK, C.R. & WEKSLER, B.B. (1981b). Recovery of prostacyclin production by de-endothelialized rabbit aorta. Critical role of neointimal smooth muscle cells. J. clin. Invest., 67, 735–741. 10.1172/JCI110090 CASPubMedWeb of Science®Google Scholar ELDOR, A., HOOVER, E.L., PETT, S.B. JR., GAY, W.A. JR., ALONSO, D.R. & WEKSLER, B.B. (1981a). Prostacyclin production by arterialized autogenous venous grafts in dogs. Prostaglandins, 22, 485–498. 10.1016/0090-6980(81)90108-8 CASPubMedWeb of Science®Google Scholar ELDOR, A. & WEKSLER, B.B. (1979). Heparin and dextran sulfate antagonize PGI2 inhibition of platelet aggregation. Thrombosis Res., 16, 617–628. 10.1016/0049-3848(79)90206-8 CASPubMedWeb of Science®Google Scholar EULER, U.S. VON. (1934). Zur Kenntnis der pharmakologischen wirkungen von Nativsekreten und Extrakten mannlicher accessorischer Geschelechtsdrusen. Naunyn Schmiedebergs Arch. exp. Path. Pharmak., 175, 78–84. 10.1007/BF01861161 CASGoogle Scholar EULER, U.S. VON & GADDUM, J.H. (1931). An unidentified depressor substance in certain tissue extracts. J. Physiol., 72, 74–87. 10.1113/jphysiol.1931.sp002763 PubMedGoogle Scholar FELDBERG, W. & GADDUM, J.H. (1934). The chemical transmitter at synapses in a sympathetic ganglion. J. Physiol., 81, 305–319. 10.1113/jphysiol.1934.sp003137 CASPubMedWeb of Science®Google Scholar FELDBERG, W., GUPTA, K.P., MILTON, A.S. & WENDLANDT, S. (1973). Effect of pyrogen and antipyretics on prostaglandin activity in cisternal C.S.F. of unanaesthetized cats. J. Physiol., 234, 279–303. 10.1113/jphysiol.1973.sp010346 CASPubMedWeb of Science®Google Scholar FERREIRA, S.H. & VANE, J.R. (1967). Prostaglandins: Their disappearance from and release into the circulation. Nature, Lond., 216, 868–873. 10.1038/216868a0 CASPubMedWeb of Science®Google Scholar FEUERSTEIN, N. & RAMWELL, P.W. (1981). OKY-1581, a potential selective thromboxane synthetase inhibitor. Eur. J. Pharmac., 69, 533–534. 10.1016/0014-2999(81)90464-7 CASPubMedWeb of Science®Google Scholar FIDLER, J., BENNETT, M.J., SWIET, M. DE, ELLIS, C. & LEWIS, P.J. (1980). Treatment of pregnancy hypertension with prostacyclin. Lancet, ii, 31–32. 10.1016/S0140-6736(80)92904-9 Google Scholar FIDLER, J., ELLIS, C., BENNETT, M.J., SWIET, M. DE & LEWIS, P.J. (1981). Prostacyclin and pre-eclamptic toxaemia In Clinical Pharmacology of Prostacyclin. ed. P.J. Lewis & J. O'Grady pp. 141–143. New York: Raven Press. Web of Science®Google Scholar FITZGERALD, G.A., FRIEDMAN, L.A., MIYAMORI, I., O'GRADY, J. & LEWIS, P.J. (1979). A double blind placebo controlled crossover study of prostacyclin in man. Life Sci., 25, 665–672. 10.1016/0024-3205(79)90507-1 CASPubMedWeb of Science®Google Scholar FITZGERALD, G.A., ROBERTS, L.J. II, MAAS, D., BRASH, A.R. & OATES, J.A. (1981). Intravenous prostacyclin in thrombotic thrombocytopenic purpura In Clinical Pharmacology of Prostacyclin. ed. P.J. Lewis & J. O'Grady p. 81. New York: Raven Press. Google Scholar FLETCHER, R. & RAMWELL, P. (1980). Prostaglandins in shock: to give or to block Adv. on Shock Res., 3, 57–66. CASPubMedGoogle Scholar FLOWER, R.J. (1978). Steroidal anti-inflammatory drugs as inhibitors of phospholipase A2 In Advances in Prostaglandin and Thromboxane Research ed. R. Paoletti & B. Samuelsson pp. 105–112. New York: Academic Press. Google Scholar FLOWER, R.J. & BLACKWELL, G.J. (1976). The importance of phospholipase A2 in prostaglandin biosynthesis. Biochem. Pharmac., 25, 285–291. 10.1016/0006-2952(76)90216-1 CASPubMedWeb of Science®Google Scholar FLOWER, R.J. & CARDINAL, D.C. (1979). Use of a novel platelet aggregometer to study the generation by, and actions of prostacyclin in whole blood In Prostacyclin. ed. J.R. Vane & S. Bergström pp. 211–220. New York: Raven Press. Google Scholar GADDUM, J.H. (1959). Bioassay procedures. Pharmac. Rev., 11, 241–249. CASPubMedWeb of Science®Google Scholar GADDUM, J.H., PEART, W.S. & VOGT, M. (1949). The estimation of adrenaline and allied substances in blood. J. Physiol., 108, 467–481. 10.1113/jphysiol.1949.sp004350 CASPubMedWeb of Science®Google Scholar GERBER, J.C., PAYNE, N.A., MURPHY, R.C. & NIES, A.S. (1981). Prostacyclin produced by the pregnant uterus in the dog may act as a circulating vasodepressor substance. J. clin. Invest., 67, 632–636. 10.1172/JCI110077 CASPubMedWeb of Science®Google Scholar GIMENO, M.J., STERIN-BORDA, L., BORDA, E.S., LAZZARI, M.A. & GIMENO, A.L. (1980). Human plasma transforms prostacyclin (PGI2) into a platelet antiaggregatory substance which contracts isolated bovine coronary arteries. Prostaglandins, 19, 907–916. 10.1016/0090-6980(80)90125-2 CASPubMedWeb of Science®Google Scholar GIMSON, A.E.S., CANALESE, J., HUGHES, R.D., LANGLEY, PC, MELLON, P.J. AND WILLIAMS, R. (1981). Treatment of fulminant hepatic failure In Clinical Pharmacology of Prostacyclin. ed. P.J. Lewis & J. O'Grady pp. 211–218. New York: Raven Press. Google Scholar GIMSON, A.E.S., HUGHES, R.D., MELLON, P.J., WOODS, H.F., LANGLEY, P.G., CANALESE, J., WILLIAMS, R. & WESTON, M.J. (1980). Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet, i, 173–175. 10.1016/S0140-6736(80)90661-3 Google Scholar GLAVIND, J., HARTMANN, S., CLEMMESEN, J., JESSEN, K.E. & DAM, H. (1952). Studies on the role of lipoperox-ides in human pathology. II. The presence of peroxidized lipids in the atherosclerotic aorta. Acta path, microbiol scand., 30, 1–6. 10.1111/j.1699-0463.1952.tb00157.x CASPubMedWeb of Science®Google Scholar GODAL, H.C., EIKA, C., DYBDAHL, J.H., DAAE, L. & LARSEN, S. (1979). Aspirin and bleeding time. Lancet, i, 1236. 10.1016/S0140-6736(79)91911-1 CASGoogle Scholar GOEHLERT, U.G., KIN, NG YING N.M.K. & WOLFE, L.S. (1981). Biosynthesis of prostacyclin in rat cerebral micro vessels and the choroid plexus. J. Neurochem, 36, 1192–1201. 10.1111/j.1471-4159.1981.tb01718.x CASPubMedWeb of Science®Google Scholar GOLDBLATT, M.W. (1933). A depressor substance in seminal fluid. J. Soc. Chem. Ind. (Lond.), 52 1056–1057. Google Scholar GOLDSTEIN, I.M., MALMSTEN, C.L., KAPLAN, H.B., KINDAHL, H., SAMUELSSON, B. & WEISSMAN, G. (1977). Thromboxane generation by stimulated human granulocytes: Inhibition by glucocorticoids and superoxide dismutase. Clin. Res., 25, 518A. Google Scholar GORMAN, R.R., BUNTING, S. & MILLER, O.V. (1977). Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins, 13, 377–388. 10.1016/0090-6980(77)90018-1 CASPubMedWeb of Science®Google Scholar GORMAN, R.R., HAMILTON, R.D. & HOPKINS, N.K. (1979). Stimulation of human foreskin fibroblast adenosine 3′:5′-cyclic monophosphate levels by prostacyclin (prostaglandin I2). J. biol Chem., 254, 1671–1676. CASPubMedWeb of Science®Google Scholar GROSE, J.H., LEBEL, M. & GBEASSOR, F.M. (1980). Diminished urinary prostacyclin metabolite in essential hypertension. Clin. Sci., 59, 121s–123s. 10.1042/cs059121s CASPubMedWeb of Science®Google Scholar GRYGLEWSKI, R.J. (1979). Prostacyclin as a circulatory hormone. Biochem. Pharmac., 28, 3161–3166. 10.1016/0006-2952(79)90055-8 CASPubMedWeb of Science®Google Scholar GRYGLEWSKI, R.J. (1980). Release of prostacyclin by almitrine. Clin. Resp. Phys., 16, 206P. Google Scholar GRYGLEWSKI, R.J., BUNTING, S., MONCADA, S., FLOWER, R.J. & VANE, J.R. (1976). Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from a prostaglandin endoperoxide. Prostaglandins, 12, 685–714. 10.1016/0090-6980(76)90047-2 CASPubMedWeb of Science®Google Scholar GRYGLEWSKI, R.J., KORBUT, R. & OCETKIEWICZ, A.C. (1978). Generation of prostacyclin by lungs in vivo and it release into the arterial circulation. Nature, Lond., 273, 765–767. 10.1038/273765a0 CASPubMedWeb of Science®Google Scholar GRYGLEWSKI, R.J., SALMON, J.A., UBATUBA, F.B., WEATHERLEY, B.C., MONCADA, S. & VANE, J.R. (1979). Effects of all cis-5,8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation. Prostaglandins, 18, 453–478. 10.1016/S0090-6980(79)80063-5 CASPubMedWeb of Science®Google Scholar GRYGLEWSKI, R.J. & SZCZEKLIK, A. (1981). Prostacyclin and atherosclerosis In Clinical Pharmacology of Prostacyclin. ed. P.J. Lewis & J. O'Grady pp. 89–95. New York: Raven Press. Google Scholar GRYGLEWSKI, R.J. & VANE, J.R. (1972). The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti-inflammatory drugs. Br. J. Pharmac., 45, 37–47. 10.1111/j.1476-5381.1972.tb09574.x CASPubMedWeb of Science®Google Scholar GULLNER, H.-G., CERLETTI, C., BARTTER, F.C., SMITH, J.B. & GILL, J.R. JR. (1979). Prostacyclin overproduction in Bartter's syndrome. Lancet, ii, 767–768. 10.1016/S0140-6736(79)92116-0 Google Scholar HAEGER, K. (1968). The treatment of peripheral occlusive arterial disease with alpha-tocopherol as compared with vasodilator agents and antiprothrombin. Vasc. Dis., 5, 199–213. CASPubMedGoogle Scholar HALL, R.J.C. & DEWAR, H.A. (1981). Safety of coronary arterial prostacyclin infusion. Lancet, i, 949. 10.1016/S0140-6736(81)91648-2 Google Scholar HAMBERG, M. & SAMUELSSON, B. (1974a). Novel transformation of arachidonic acid in human platelets. Proc. natn. Acad. Sci. U.S.A., 71, 3400–3404. 10.1073/pnas.71.9.3400 CASPubMedWeb of Science®Google Scholar HAMBERG, M. & SAMUELSSON, B. (1974b). Prostaglandin endoperoxides. VII. Novel transformations of arachidonic acid in guinea pig lungs. Biochem. biophys. Res. Commun., 61, 942–949. 10.1016/0006-291X(74)90246-0 CASPubMedWeb of Science®Google Scholar HAMBERG, M., SVENSSON, J. & SAMUELSSON, B. (1974a). Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc. natn. Acad. Sci. U.S.A., 71, 3824–3828. 10.1073/pnas.71.10.3824 CASPubMedWeb of Science®Google Scholar HAMBERG, M., SVENSSON, J. & SAMUELSSON, B. (1975). Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. natn. Acad. Sci. U.S.A., 72, 2994–2998. 10.1073/pnas.72.8.2994 CASPubMed
Referência(s)